如何引证项目

血清MMP-2，AFP与MELD评分对HBV相关慢加急性肝衰竭患者预后的评估价值

   
@article{LCBL33584,
	author = {君 杨 和 洋辉 黄},
	title = {血清MMP-2，AFP与MELD评分对HBV相关慢加急性肝衰竭患者预后的评估价值},
	journal = {临床与病理杂志},
	volume = {39},
	number = {8},
	year = {2019},
	keywords = {},
	abstract = {目的：探讨基质金属蛋白酶-2(matrix metalloproteinase-2，MMP-2)、甲胎蛋白(alpha fetoprotein，AFP)水平与终末期肝病模型(model for end-stage liver disease，MELD)评分对HBV相关慢加急性肝衰竭(HBV-related acute on chronic liver failure，HBV-ACLF)患者预后评估价值。方法：根据患者临床转归情况将90例HBV-ACLF患者分为生存组和死亡组。比较两组患者血清MMP-2，AFP水平与MELD评分差异，logistic回归分析各指标与患者预后的关系，分析MMP-2、AFP水平与MELD评分对HBV-ACLF患者预后的评估价值。结果：死亡组血清MMP-2水平及MELD评分均高于生存组，而血清AFP水平则显著低于生存组(P},
	url = {https://lcbl.amegroups.com/article/view/33584}
}